OnBioVC

AgaMatrix, Inc.: Series C $23.7M

arubenstein — Sun, 20 Jan 2008 01:12:53 +0000

AgaMatrix (Salem, NH) maker of blood glucose monitoring systems that provide results to help users better manage their diabetes closed a $23.7M Series C financing. Participants include Ferrer Freeman & Co.

PeptImmune, Inc.: Series D $8.2M

arubenstein — Sun, 20 Jan 2008 01:09:55 +0000

PeptImmune Inc. (Cambridge, MA) a clinical stage biotechnology company utilizing novel and proven technologies to improve the therapeutic management of chronic autoimmune and metabolic disorders such as pemphigus vulgaris and multiple sclerosis has closed on the first $8.2M traunche of a Series D financing. Participants include New Enterprise Associates, MPM Capital, Hunt Ventures, Boston Medical Ventures and Silicon Valley Bank Capital.

Pervasis Therapeutics, Inc.: Series B $9.75M

arubenstein — Sun, 20 Jan 2008 01:07:49 +0000

Pervasis Therapeutics (Cambridge, MA) is working to regulate vascular repair and restore natural blood flow to critical organs in end-stage renal disease closed a $9.75M Series B financing. Participants include Flagship Venture Partners, Polaris Venture Partners, Highland Capital Partners, and Musket Research Associates.

ProtAffin Biotechnologie, AG: Series B €4.0M

arubenstein — Sun, 20 Jan 2008 01:06:27 +0000

ProtAffin Biotechnologie (Austria) is focused on developing novel biotechnology therapeutic products for acute and chronic inflammatory diseases has closed a €4.0M Series A financing. Participants include The Entrepreneurs Fund BV, Aescap Venture Management and Z-Cube.

Aushon Biosystems, Inc.: Series B $7.0M

arubenstein — Sun, 20 Jan 2008 01:05:27 +0000

Aushon Biosystems (Burlington, MA) provides advanced microarray technologies to life science research, drug discovery, development and clinical diagnostics closed on a $4M traunche $7M Series B. Participant was North Bridge Venture Partners.

AmpliMed Corp.: Series C $22.0M

arubenstein — Sun, 20 Jan 2008 01:04:13 +0000

AmpliMed (Tucson, AZ) a clinical-stage pharmaceutical company with Phase II lead compounds for malignant melanoma and pancreatic cancer closed on $5M traunche of a $22M Series C financing. Participants include BioMed Venture Partners, Biotech Insight Ventures, Solstice Capital and Valley Ventures.

Autonomic Technologies, Inc.: Series A $5.0M

arubenstein — Sun, 20 Jan 2008 00:59:33 +0000

Autonomic Technologies (Menlo Park, CA) makers of neuromdoulation stimulation devices closed on the first $3M traunche of a $5M Series A financing. Participants in the round include Kleiner Perkins Caufield & Byers and the Cleveland Clinic.

Aerovance, Inc.: Series C $60M

arubenstein — Thu, 11 Oct 2007 04:27:24 +0000

Aerovance (Berkeley, CA) a biopharmaceutical company focused on the development asthma, cystic fibrosis and chronic obstructive pulmonary disease has closed a $60M Series C. Participants in the round included Apax Partners, Clarus Ventures, Alta Partners, Lehman Brothers, NGN Capital and Burrill & CO.

OnBioVC 1Q07 Summary

arubenstein — Tue, 03 Apr 2007 16:02:00 +0000

Here it is, hot off the press…An effort to aggregate all of the data that is found here at OnBioVC. To download the report please click (here) or paste the following link in your browser to grab the .pdf.:

http://ab.rubenstein.googlepages.com/home

Please forward all comments and criticisms to: arubenstein@rnaventures.com

Endocyte, Inc.: Series C $15M

arubenstein — Mon, 02 Apr 2007 18:20:00 +0000

Endocyte (West Lafayette, IN) developer of folate-targeted based therapeutics for the treatment of renal cell carcinoma, ovarian, endometrial and nscl cancer raised $15M in a Series C financing. Participants included Sanderling Ventures, Burrill & Company, Triathlon Medical Ventures, Blue Chip Venture Company, American Bailey Ventures and CID Capital.